Angela A. Armstrong

Array ( [id] => 17672707 [patent_doc_number] => 20220185874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => NOVEL ANTI-TROPONINT ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/666921 [patent_app_country] => US [patent_app_date] => 2022-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17666921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19368344 [patent_doc_number] => 12060415 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => GRP78-binding antibodies and uses thereof and selection of phage-displayed accessible recombinant targeted antibodies [patent_app_type] => utility [patent_app_number] => 17/592828 [patent_app_country] => US [patent_app_date] => 2022-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 41 [patent_no_of_words] => 29279 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17592828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666300 [patent_doc_number] => 11773178 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Antagonistic CD40 monoclonal antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/588518 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 15356 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17588518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945762 [patent_doc_number] => 20220332779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => INTERLEUKIN 15 FUSION PROTEIN FOR TUMOR TARGETING THERAPY [patent_app_type] => utility [patent_app_number] => 17/588880 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17588880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17988795 [patent_doc_number] => 20220354832 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => METHODS FOR TREATING AORTIC VALVE STENOSIS WITH A HEDGEHOG PATHWAY INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/584031 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17584031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595389 [patent_doc_number] => 20220144962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/579468 [patent_app_country] => US [patent_app_date] => 2022-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15229 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17579468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17612013 [patent_doc_number] => 20220154292 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => METHODS OF DIAGNOSING, DETERMINING THE PROGRESSION OF, AND TREATING A PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 17/579355 [patent_app_country] => US [patent_app_date] => 2022-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33634 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17579355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548173 [patent_doc_number] => 20220119514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => METHODS FOR ALTERING BODY COMPOSITION BY ADMINISTERING A GDF8 INHIBITOR AND AN ACTIVIN A INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/570128 [patent_app_country] => US [patent_app_date] => 2022-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17570128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792089 [patent_doc_number] => 20220251180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => ANTI-APOC3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/646538 [patent_app_country] => US [patent_app_date] => 2021-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33982 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17646538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17734734 [patent_doc_number] => 20220220193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/645760 [patent_app_country] => US [patent_app_date] => 2021-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17645760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19423785 [patent_doc_number] => 12083176 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-10 [patent_title] => Human antibodies to PCSK9 for use in methods of treating particular groups of subjects [patent_app_type] => utility [patent_app_number] => 17/560402 [patent_app_country] => US [patent_app_date] => 2021-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 65638 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17837747 [patent_doc_number] => 20220275052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/560022 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17837747 [patent_doc_number] => 20220275052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/560022 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687742 [patent_doc_number] => 20220195034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => NEUTRALIZING ANTIBODIES TO HUMAN ENDOTHELIN [patent_app_type] => utility [patent_app_number] => 17/645211 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20636 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17645211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19411774 [patent_doc_number] => 12077581 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => Anti-PACAP antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/553280 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 77 [patent_figures_cnt] => 246 [patent_no_of_words] => 124338 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520519 [patent_doc_number] => 20220106368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => IMMUNOGENIC FRAGMENT PEPTIDE OF EN2 PROTEIN OR ANTIBODY COMPOSITION SPECIFICALLY RECOGNIZING SAME [patent_app_type] => utility [patent_app_number] => 17/553779 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7561 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520520 [patent_doc_number] => 20220106369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => IMMUNOGENIC FRAGMENT PEPTIDE OF EN2 PROTEIN OR ANTIBODY COMPOSITION SPECIFICALLY RECOGNIZING SAME [patent_app_type] => utility [patent_app_number] => 17/553790 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520520 [patent_doc_number] => 20220106369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => IMMUNOGENIC FRAGMENT PEPTIDE OF EN2 PROTEIN OR ANTIBODY COMPOSITION SPECIFICALLY RECOGNIZING SAME [patent_app_type] => utility [patent_app_number] => 17/553790 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520520 [patent_doc_number] => 20220106369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => IMMUNOGENIC FRAGMENT PEPTIDE OF EN2 PROTEIN OR ANTIBODY COMPOSITION SPECIFICALLY RECOGNIZING SAME [patent_app_type] => utility [patent_app_number] => 17/553790 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520520 [patent_doc_number] => 20220106369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => IMMUNOGENIC FRAGMENT PEPTIDE OF EN2 PROTEIN OR ANTIBODY COMPOSITION SPECIFICALLY RECOGNIZING SAME [patent_app_type] => utility [patent_app_number] => 17/553790 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553790 [rel_patent_id] =>[rel_patent_doc_number] =>)